13G Filing: James E. Flynn and Audentes Therapeutics Inc (BOLD)

Page 4 of 18

Page 4 of 18 – SEC Filing

CUSIP No.
05070R104
13G
Page 4 of 15
1.
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Deerfield Management Company,
L.P.
2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
  (a) o
  (b) ý
3.
SEC USE ONLY
4.
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware


NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.
SOLE VOTING POWER
 
0
6.
SHARED VOTING POWER
 
2,103,653 (3)
7.
SOLE DISPOSITIVE POWER
 
0
8.
SHARED DISPOSITIVE POWER
 
2,103,653 (3)
9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
2,103,653 (3)
10.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
o
11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
 
7.59%
12.
TYPE OF REPORTING PERSON*
 
PN
_________________
(3)
Comprised of Common Stock held by Deerfield Private Design Fund III, L.P., Deerfield Special Situations Fund, L.P.,
Deerfield Partners, L.P. and Deerfield International Master Fund, L.P., of which Deerfield Management Company, L.P. is the
investment advisor.

Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)

Page 4 of 18